Understand the gastrointestinal partnering landscape using intelligence from 438 real-world collaboration and licensing deals.
Gastrointestinal Collaboration and Licensing Deals 2016-2026 provides comprehensive intelligence on 438 partnering deals involving gastrointestinal assets, technologies and development programs.
Gastrointestinal partnering encompasses a diverse range of therapeutic indications, technologies and development stages, with transactions ranging from early research collaborations through to licensing, development and commercialization agreements.
The report brings this activity together in one resource, enabling users to understand who is partnering, which gastrointestinal opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across therapeutic indications, technologies and stages of development.
Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.
It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in gastrointestinal partnering.
This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
Financial benchmarks are most useful when interpreted alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
The report analyzes deals by gastrointestinal therapeutic indication, allowing users to move beyond broad market-level benchmarks and focus on transactions most relevant to a particular program or strategic interest.
Combined with analysis by technology and development stage, this enables users to identify more meaningful comparable transactions and prospective partners.
Identify comparable gastrointestinal transactions, prospective partners and relevant deal structures.
Search and Evaluation teams
Understand which companies are actively seeking gastrointestinal opportunities across particular indications, technologies and development stages.
Biotechnology Companies Seeking Partners
Identify organizations with demonstrated interest in comparable gastrointestinal assets and technologies.
Corporate and R&D Strategy teams
Understand how competitors and prospective partners are building gastrointestinal pipelines through external innovation.
Competitive and Market Intelligence teams
Track partnering activity by company, indication, development stage and technology to understand evolving strategic priorities.
Legal and Transaction teams
Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
The briefing applies the underlying gastrointestinal deal intelligence to the customer's own asset, technology, indication or partnering objectives.
Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
Gastrointestinal Collaboration and Licensing Deals 2016-2026 provides comprehensive intelligence on 438 partnering deals involving gastrointestinal assets, technologies and development programs.
Gastrointestinal partnering encompasses a diverse range of therapeutic indications, technologies and development stages, with transactions ranging from early research collaborations through to licensing, development and commercialization agreements.
The report brings this activity together in one resource, enabling users to understand who is partnering, which gastrointestinal opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across therapeutic indications, technologies and stages of development.
Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.
It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in gastrointestinal partnering.
Understand the gastrointestinal partnering landscape
The report analyzes gastrointestinal dealmaking from 2016 to 2026, including:
- Trends in gastrointestinal partnering by year
- Deal activity by deal type
- Industry sector
- Stage of development at the time of partnering
- Technology type
- Gastrointestinal therapeutic indication
- Most active gastrointestinal dealmakers
- Leading deals by disclosed value
- How gastrointestinal partnering activity is evolving
Benchmark gastrointestinal deal financials
Financial terms can vary considerably according to the asset, development stage, technology, rights granted and overall transaction structure.The report provides dedicated analysis of disclosed financial terms, including:
- Headline deal values
- Upfront payments
- Milestone payments
- Royalty rates
This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
Financial benchmarks are most useful when interpreted alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
Identify leading gastrointestinal dealmakers and prospective partners
The report identifies the most active companies in gastrointestinal partnering and provides transaction histories that enable users to investigate their previous activity.This can help users identify:
- Companies actively seeking gastrointestinal opportunities
- Prospective licensing and collaboration partners
- Organizations repeatedly partnering in particular gastrointestinal indications
- Companies active at relevant stages of development
- Dealmakers demonstrating interest in specific technologies or approaches
- Competitors pursuing similar external innovation strategies
Compare partnering activity across gastrointestinal indications
Gastrointestinal disease encompasses multiple therapeutic indications with differing scientific, clinical and commercial dynamics.The report analyzes deals by gastrointestinal therapeutic indication, allowing users to move beyond broad market-level benchmarks and focus on transactions most relevant to a particular program or strategic interest.
Combined with analysis by technology and development stage, this enables users to identify more meaningful comparable transactions and prospective partners.
Understand how gastrointestinal agreements are structured
The report includes collaboration, licensing, development, research and other partnering transactions.Depending on the transaction and available disclosure, users can investigate areas including:
- Rights granted and retained
- Research and development responsibilities
- Licensing rights
- Exclusivity
- Geographic rights
- Intellectual property
- Development and regulatory obligations
- Manufacturing and supply responsibilities
- Commercialization rights
- Financial consideration
- Milestones and royalties
- Governance
- Term and termination provisions
Learn from real-world contract documents
Where publicly available, the report provides access to underlying contract documents for selected gastrointestinal transactions.These agreements can provide substantially more detail than headline announcements alone, enabling users to examine how companies have documented areas such as:
- Scope of rights
- Development obligations
- Intellectual property
- Exclusivity
- Financial terms
- Milestone triggers
- Royalty provisions
- Commercialization rights
- Termination and other negotiated provisions
Comprehensive gastrointestinal deal directory
The report includes a comprehensive directory of 438 gastrointestinal collaboration and licensing deals, providing a detailed resource for identifying relevant precedent transactions.Deals can be reviewed by:
- Company
- Technology type
- Therapeutic indication
- Contract availability
Who should use this report?
Business Development and Licensing teamsIdentify comparable gastrointestinal transactions, prospective partners and relevant deal structures.
Search and Evaluation teams
Understand which companies are actively seeking gastrointestinal opportunities across particular indications, technologies and development stages.
Biotechnology Companies Seeking Partners
Identify organizations with demonstrated interest in comparable gastrointestinal assets and technologies.
Corporate and R&D Strategy teams
Understand how competitors and prospective partners are building gastrointestinal pipelines through external innovation.
Competitive and Market Intelligence teams
Track partnering activity by company, indication, development stage and technology to understand evolving strategic priorities.
Legal and Transaction teams
Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
Turn market-wide gastrointestinal intelligence into company-specific insight
For qualifying customers, the analyst can also provide a Customized Executive Partnering Briefing alongside the report.The briefing applies the underlying gastrointestinal deal intelligence to the customer's own asset, technology, indication or partnering objectives.
Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
Table of Contents
Executive SummaryChapter 1 - Introduction
Chapter 2 - Trends in gastrointestinal dealmaking
Chapter 3 - Financial deal terms for gastrointestinal partnering
Chapter 4 - Leading gastrointestinal deals and dealmakers
Chapter 5 - Gastrointestinal contract document directory
Chapter 6 - Gastrointestinal dealmaking by therapeutic target
Deal directory
Table of figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4D Pharma
- 4SC
- 9 Meters Biopharma
- Aayam Therapeutics
- Abbvie
- Ab E Discovery
- Aclipse Therapeutics
- AdaptivEndo
- AdaptVac
- Adiso Therapeutics
- ADL Bionatur Solutions
- Advanced Biological Laboratories
- Aerpio Pharmaceuticals
- Aevi Genomic Medicine
- AgomAb Therapeutics
- AIG Hospitals
- AI Medical Service
- Akebia Therapeutics
- Alba Therapeutics
- Alfasigma
- Alimentiv
- Alivio Therapeutics
- Allergan
- Allied Digestive Health
- Alma Bio Therapeutics
- Alvit LCS Pharma
- Alvotech
- Amarex Clinical Research
- Ambry Genetics
- Ambu
- Amgen
- AnimalBiome
- Anokion
- Antibe Therapeutics
- Apogee Biotechnology
- Applied BioMath
- Arcadia Consumer Healthcare
- Ardelyx
- Arena Pharmaceuticals
- Ariel Precision Medicine
- Aristea Therapeutics
- Artios Pharma
- Artizan Biosciences
- Asahi Kasei
- AscentX Medical
- Aslan Pharma
- Assembly Biosciences
- Associazione Poic e Dintorni APS
- Astellas Pharma
- AstraZeneca
- Asymchem Laboratories
- Athos Therapeutics
- Atlantic Healthcare
- Australasian Gastro Intestinal Research Foundation
- Aziyo Biologics
- AzurRx BioPharma
- Back-A-Line
- Bausch Health Companies
- Baxter International
- Bazelet
- BDD Pharma
- Beacon Discovery
- BenevolentAI
- Bharat Biotech
- BigHat Biosciences
- Bill and Melinda Gates Foundation
- BinnoPharm
- Bio-Me
- Bio-Rad Laboratories
- Bio-Thera Solutions
- BioClinica
- Biocodex Microbiota Foundation
- BioDelivery Sciences
- Biodexa Pharmaceuticals
- Biofortis
- Biogen
- Biohaven Pharmaceuticals
- Biolojic Design
- BiomeBank
- BioMed X Innovation Center
- Biomerica
- Biomica
- BiomX
- BioRap Technologies
- Biossil
- Biostage
- BioSurfaces
- Boehringer Ingelheim
- Boston Pharmaceuticals
- Braintree Laboratories
- Bridge Biotherapeutics
- Brigham and Women's Hospital
- Bristol-Myers Squibb
- C4X Discovery
- California Institute of Technology
- Calypso Biotech
- Camargo Pharmaceutical Services
- CannaKids
- Cannex Scientific
- Cantel Medical
- Capsulomics
- Captor Therapeutics
- Cara Care
- Carbiotix
- Case Western Reserve University
- Catholic University Leuven
- CB2 Therapeutics
- Cedars-Sinai Medical Center
- Celgene
- Celiac Disease Foundation
- Celltrion
- Celsius Therapeutics
- Censis Technologies
- Centers for Disease Control and Prevention
- Cerevance
- Cernostics
- Charles River Laboratories
- Cheplapharm Arzneimittel
- Chinese University of Hong Kong
- Chong Kun Dang
- CHU Sainte-Justine
- Cipher Pharmaceuticals
- Cipla
- Cleveland Clinic
- Clinical Enterprise
- Codexis
- Collplant
- Colonoscopy Clinic
- ConvaTec
- Cook Biotech
- Cooper Pharma
- Cornell University
- Cosmo Pharmaceuticals
- COUR Pharmaceutical
- Creapharm
- CRH Medical
- Crohn's and Colitis Foundation of America
- CRS Bio
- Curant Health
- CURE Pharmaceutical
- Cyclerion Therapeutics
- Cytocom
- CytoReason
- Daewoong Pharmaceutical
- Daiichi Sankyo
- Dalriada Drug Discovery
- Danish Innovation Fund
- DayTwo
- Debiopharm
- Deciphex
- Delphi Genetics
- Department of Defense
- Dermira
- Dignify Therapeutics
- Diversigen
- DNAnexus
- Dong-A ST
- Dr. Falk Pharma
- Dr. Reddy's Laboratories
- Duke Clinical Research Institute (DCRI)
- Duke University
- EA Pharma
- Earendil Labs
- ECM Therapeutics
- Eisai
- Elanco
- Eli Lilly
- Emtora Biosciences
- Emulate
- EndoLogic
- enGene
- Engitix
- Ensho Therapeutics
- Entera Health
- Enterome Bioscience
- Entrinsic Health Solutions
- Equillium
- EsoCap
- Esteve
- EtectRx
- Eton Pharmaceuticals
- Eunice Kennedy Shriver Institute of Child Health and Human Development
- European Union
- Evoke Pharma
- Evolve BioSystems
- Evommune
- EVOQ Therapeutics
- Evotec
- Faes Farma
- Felix Biotechnology
- Ferring Pharmaceuticals
- Finch Therapeutics
- First Wave Bio
- Food Marble Digestive Health
- Formation Bio
- Fosun Pharmaceutical
- Foundation for Celiac Disease Outcome Measures
- French National Institute for Agricultural Research
- Fresenius Kabi Pharmaceuticals
- FSD Pharma
- Fujifilm Kyowa Kirin Biologics
- Functional Gut Diagnostics
- FutureGen Biopharm
- Future Pak
- Galapagos
- Gedeon Richter
- Genentech
- Geneoscopy
- General Automation Lab Technologies
- Genetic Analysis
- Genomic Biopharma
- Genten Therapeutics
- GentiBio
- Georgia State University
- Giiant Pharma
- Gilead Sciences
- Ginkgo BioWorks
- GI OnDEMAND
- GI Partners of Illinois
- GI Reviewers
- Gossamer Bio
- Greenstone Biosciences
- GSK
- Gusto Global
- Hadasit Bioholdings
- Haisco Pharmaceutical
- Halozyme Therapeutics
- Hanmi Pharmaceutical
- Harvest Capital Strategies
- Helsinn Healthcare
- Helsinn Therapeutics
- Hepion Pharmaceuticals
- HiFiBio
- Highland Therapeutics
- HK inno.N
- Hollister-Stier Labs
- Holobiome
- Horizon Europe
- Hoth Therapeutics
- Hudson Institute of Medical Research
- Hyloris Pharmaceuticals
- I-mab
- Iambic Therapeutics
- Idera Pharmaceuticals
- Illumina
- IMIDomics
- Immunai
- Immune Pharmaceuticals
- Immune Therapeutics
- ImmuNext
- Immunic
- ImmunogenX
- Imperial College London
- InDex Pharmaceuticals
- Innate Pharma
- Innovate Biopharmaceuticals
- Innovate UK
- Innovation Pharmaceuticals
- Innovet
- Inotrem
- InQpharm
- Institut Gustave Roussy
- Instituto de Ciencias Farmaceuticas
- Intact Therapeutics
- Intas Pharmaceuticals
- Integrated Gut Health
- International Centre for Diarrhoeal Disease Research
- Intract Pharma
- Intrexon
- IntroMedic
- InveniAI
- Ionis Pharmaceuticals
- Ipsen
- IQVIA
- Ironwood Pharmaceuticals
- ISOThrive
- Iterative Health
- Iterative Scopes
- Jaguar Health
- Janssen Biotech
- Janssen Pharmaceuticals
- Janssen Pharmaceutica NV
- Janssen Research & Development
- Janssen Sciences
- Jitsubo
- Johns Hopkins University
- Johnson & Johnson
- Johnson & Johnson Consumer Companies
- Johnson & Johnson Innovation
- JSR
- Juntendo University
- Juventas Therapeutics
- Kaken Pharmaceutical
- Kallyope
- Kansas University Medical Center (KUMC)
- Karolinska Institute
- Keio Gijuku University
- Kenneth Rainin Foundation (KRF)
- Kings College London
- Knight Therapeutics
- Korea Pharma
- Kwang Dong Pharmaceutical
- Kyowa Hakko Kirin
- Laboratories Acbel
- Lahey Hospital & Medical Center
- Lamassu Pharma
- Landos Biopharma
- Leiden University
- Leona M and Harry B Helmsley Charitable Trust
- Les Laboratoires Servier
- LianBio
- LimmaTech Biologics
- LiveLeaf
- LMU University Hospital Munich
- LNC
- Lucid Diagnostics
- Luminex
- Lupin
- Lynx.MD
- Mabwell Bioscience
- Magellan Health Services
- Marinomed Biotechnologie
- Martin Pharmaceuticals
- Massachusetts General Hospital
- Massachusetts Institute of Technology
- Mayo Clinic
- McMaster University
- Medgenics
- MediBeacon
- Medical University of Graz
- Medical University of Vienna
- MedImmune
- Medtronic
- Meiji Seika
- Memorial Hermann Health System
- Memorial Sloan Kettering Cancer Center
- Merck and Co
- Mesoblast
- Metabiomics
- Metabolon
- Microba Life Sciences
- Microbiotica
- Millennium
- Mimetas
- Mission Cure
- MiTest Health
- Mitsubishi Tanabe Pharma
- Momenta Pharmaceuticals
- Monash University
- Morphic Therapeutic
- Mor Research Applications
- Moss Genomics
- Motus GI Medical Technologies
- MultiPlan
- Mundipharma
- MyBiotics Pharma
- Mylan Laboratories
- Mylan Pharmaceuticals
- Napo EU
- Napo Pharmaceuticals
- National Heart
- Lung and Blood Institute
- National Institute of Allergy and Infectious Diseases
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institutes of Health
- National Resilience
- Nektar Therapeutics
- Neolaia Bio
- Neoteryx
- Nestle Health Science
- NeurAxis
- Neurogastrx
- New Day Diagnostics
- Nexilico
- NexOptic
- Nima
- Nipro Corporation
- Norgine
- Northwestern University
- North Zealand University Hospital
- Novartis
- Novartis Institute for Tropical Diseases
- Novome Biotechnologies
- NuBiyota
- Numab
- NuMedii
- Numerate
- Nutricion
- Nvidia
- NYU Langone Medical Center
- OMass Therapeutics
- OmniVision Technologies
- Onegevity
- One GI
- Opella Healthcare Group
- OpenBiome
- Orbis Medicines
- OSE Immunotherapeutics
- Otsuka America Pharmaceutical
- Ovation
- Owlstone Medical
- Palisade Bio
- Panaxia
- Paragon Bioservices
- Parexel
- Parexel Biotech
- Parvus Therapeutics
- Path BioAnalytics
- PAVmed
- PEAR Therapeutics
- Pendopharm
- Penn State Microbiome Center
- Pfizer
- PharmaBiome
- PharmaCare Management
- PhaseV
- Phathom Pharmaceuticals
- PlantEXT
- Pliant Therapeutics
- Portal Instruments
- PPD
- Pragma Bio
- Prana Biotechnology
- PredictImmune
- Premier Inc
- Prescient Medical
- Previse
- PRISM BioLab
- Probi
- Processa Pharmaceuticals
- Progenity
- Prometheus Biosciences
- Prometheus Laboratories
- Protagonist Therapeutics
- Proteic Bioscience
- Provention Bio
- PureTech Health
- Purnovate
- PvP Biologics
- Quadri Pharmaceuticals
- Qualicaps
- Qu Biologics
- Quell Therapeutics
- Quotient Clinical
- Quotient Therapeutics
- Rafa Pharmaceuticals
- Ramot at Tel Aviv University
- Rani Therapeutics
- Rasayana Therapeutics
- Rebiotix
- RedHill Biopharma
- Regeneron Pharmaceuticals
- Regentys
- Renexxion
- ReproCell
- Rho
- Ritter Pharmaceuticals
- Roche
- Roquette
- Royal College of Surgeons (Ireland)
- Salix Pharmaceuticals
- Samsung Bioepis
- Sandoz
- Sanofi
- Sano Genetics
- Satisfai Health
- SciCann Therapeutics
- Scipher Medicine
- Sebela Pharmaceuticals
- Second Genome
- Seed Mena
- Selexis
- Seres Therapeutics
- Serosep
- Shandong Luoxin Pharma
- Sheba Medical Center
- Shionogi
- Shire Pharmaceuticals
- Siemens Healthineers
- Signum Surgical
- Simcere Pharmaceutical
- Simulations Plus
- Sinorda Biomedicine
- Sinovant Sciences
- Siolta Therapeutics
- SomaLogic
- SonarMD
- Sonoma BioTherapeutics
- Sosei
- Sosei Heptares
- Spaulding Clinical Research
- Stanford University School of Medicine
- Starton Therapeutics
- Statera Biopharma
- Stella Diagnostics
- Stoked Bio
- Strand Life Sciences
- Structural Genomics Consortium
- Summit Therapeutics
- Sun Genomics
- Suono Bio
- Sutter Health
- Swiss Integrative Center for Human Health
- Swixx Biopharma
- Symbiotix Biotherapies
- Synergy Pharmaceuticals
- Synlogic
- Synthetic Biologics
- Synthon
- Takeda Pharmaceutical
- Tantu Therapeutics
- TARGET PharmaSolutions
- Telcon RF Pharmaceuticals
- Tetra Bio-Pharma
- Teva Pharmaceutical Industries
- Teva Pharmaceuticals USA
- Texas A&M Health Science Center
- The Crohn's and Colitis Foundation of Canada
- Theradiag
- Theravance
- Theravance Biopharma
- Theriva Biologics
- The Vancouver Island Health Authority
- Thorne Research
- TiGenix
- Tissium
- Tivic Health Systems
- Tiziana Life Sciences
- TScan Therapeutics
- Twist Bioscience
- Ubie
- uBiome
- Unilever
- UniQuest
- United Digestive
- Universite catholique de Louvain
- University Gastroenterology
- University Hospital of Leuven
- University of Adelaide
- University of Augsburg
- University of Birmingham
- University of British Columbia
- University of Calgary
- University of California
- San Diego
- University of California Los Angeles
- University of California San Francisco
- University of Manitoba
- University of Massachusetts
- University of Michigan
- University of North Carolina
- University of Oslo
- University of Oxford
- University of Pennsylvania
- University of Pittsburgh
- University of Sherbrooke
- University of Tokyo
- University of Washington
- University of Windsor
- Upadia
- US Government
- Utrecht University
- Valbiotis
- Valneva
- Vcell Healthcare
- V ClinBio
- VectivBio
- Vedanta Biosciences
- Verb Biotics
- Verily
- Vertex Pharmaceuticals
- Viatris
- VIPUN Medical
- Virginia Catalyst
- Virgo Surgical Video Solutions
- Virios Therapeutics
- Vital Food Processors
- Vital Therapies
- Vivante Health
- Vivelix Pharmaceuticals
- Vivtex
- Vizient
- Washington University in St Louis
- WuXi Biologics
- Yale University
- Zealand Pharma
- Zedira
- Zentiva
- Zydus Lifesciences
Methodology
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Assignment
- Co-development
- Co-market
- Co-promotion
- Collaborative R&D
- Contract service
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Loan
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Spin out
- Sub license
- Supply
- Termination
- Warrant
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Exclusivity
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
LOADING...
